A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

November 14, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

July 31, 2026

Conditions
Advanced Solid TumorsMerkel Cell Carcinoma
Interventions
DRUG

FF-10850 Topotecan Liposome Injection

FF-10850 to be diluted and infused over 60 minutes.

Trial Locations (7)

10029

Icahn School of Medicine at Mount Sinai, New York

43221

Ohio State University Wexner Medical Center, Columbus

53792

University of Wisconsin Clinical Science Center, Madison

77030

MD Anderson Cancer Center, Houston

80218

Sarah Cannon Research Institute at HealthONE, Denver

85258

HonorHealth, Scottsdale

02215

Dana Farber Cancer Institute (DFCI), Boston

All Listed Sponsors
lead

Fujifilm Pharmaceuticals U.S.A., Inc.

INDUSTRY